Uric acid (UA) is the end product of purine metabolism, and its concentration in blood can increase in humans, great apes, and dalmatian dogs as a consequence of a genetic mutation that occurred millions of years ago and contribute to human evolution from less evolved species [2]. These elevated plasma levels of UA are the final result of almost three different mechanisms under genetic control and involve UA production, renal excretion, and gut absorption [3]. Under physiological conditions, UA synthesis and excretion are balanced in the body. Once this balance is disturbed, it leads to hyperuricemia (HU). Typically, male UA levels greater than 7 mg/dL (420 μmol/L) and female UA levels greater than 6 mg/dL (360 μmol/L) are considered hyperuricemia.

Borghi C, D.J. (2021). Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. CARDIOLOGY JOURNAL, 28(1), 1-14 [10.5603/CJ.a2021.0001].

Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Borghi C
Co-primo
Conceptualization
;
2021

Abstract

Uric acid (UA) is the end product of purine metabolism, and its concentration in blood can increase in humans, great apes, and dalmatian dogs as a consequence of a genetic mutation that occurred millions of years ago and contribute to human evolution from less evolved species [2]. These elevated plasma levels of UA are the final result of almost three different mechanisms under genetic control and involve UA production, renal excretion, and gut absorption [3]. Under physiological conditions, UA synthesis and excretion are balanced in the body. Once this balance is disturbed, it leads to hyperuricemia (HU). Typically, male UA levels greater than 7 mg/dL (420 μmol/L) and female UA levels greater than 6 mg/dL (360 μmol/L) are considered hyperuricemia.
2021
Borghi C, D.J. (2021). Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. CARDIOLOGY JOURNAL, 28(1), 1-14 [10.5603/CJ.a2021.0001].
Borghi C, Domienik-Karłowicz J, Tykarski A, Widecka K, Filipiak KJ, Jaguszewski MJ, Narkiewicz K, Mancia G.
File in questo prodotto:
File Dimensione Formato  
Borghi C_Expert consensus_CardilJ2021.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 314.78 kB
Formato Adobe PDF
314.78 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/826582
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 33
social impact